Table 1. Baseline demographics and ocular characteristics for prior ranibizumab-treated patients with nAMD.
| Characteristics | Prior ranibizumab-treated patients with nAMD N = 16,167* |
|---|---|
| Patient demographics | |
| Mean (SD) age, years | 78.4 (9.0) |
| Gender, n (%) | |
| Male | 6637 (41.1) |
| Female | 9530 (59.0) |
| Race, n (%) | |
| Caucasian | 12,915 (79.9) |
| Asian | 2427 (15.0) |
| Native American | 11 (0.1) |
| Pacific Islander | 1 (0.01) |
| Black | 42 (0.3) |
| Other | 374 (2.3) |
| Ocular characteristics | |
| VA | |
| n† | 15,165 |
| Mean (SD) VA, ETDRS letters | 56.5 (20.0) |
| CRT | |
| n† | 11,639 |
| Mean (SD) CRT, μm | 279.4 (106.0) |
| IOP | |
| n† | 7911 |
| Mean (SD), mmHg | 15.3 (3.6) |
| Median time from diagnosis to first treatment, days | 557.0 |
Safety set.
* number of patients at enrollment;
†number of evaluable baseline patients.
For prior ranibizumab-treated eyes, the date of study entry was considered the baseline date.
Time since diagnosis = time between diagnosis and study entry for primary treated eyes pre-treated with ranibizumab and time between diagnosis and date of first on-study injection with ranibizumab if the primary treated eye has not been pre-treated with ranibizumab.
Patients with a baseline visit date present are included. Data collected until the last recorded follow-up date was used to perform the analyses (i.e. data for 5-year duration of the study).
N, total number of patients; n, number of patients; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; nAMD, neovascular age-related macular degeneration; SD, standard deviation; VA, visual acuity.